Supriya Lifescience Limited — Investor Meet, 04-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Supriya Lifescience Limited reported a 19% year-on-year revenue increase to ₹166 crores for Q2 FY25, with an EBITDA margin of 39% and a PAT margin of 28%. The company's export revenue rose to 83%, mainly driven by growth in Latin America. They anticipate a doubling of revenue to ₹1,000 crores by FY27, focusing on high-margin regulated markets and expanding their product line. The new Ambernath facility and Module E will significantly enhance their production capacity.